Literature DB >> 2996397

Epidemiology of human T-lymphotropic virus type III and the risk of the acquired immunodeficiency syndrome.

W A Blattner, R J Biggar, S H Weiss, M Melbye, J J Goedert.   

Abstract

The discovery of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) has opened a window to the understanding of the spectrum of the acquired immunodeficiency syndrome (AIDS) and related clinical syndromes. Analysis of risk factors for seropositivity has shown that HTLV-III is transmitted most efficiently via routes that involve close personal contact or parenteral exposure. Longitudinal studies have shown that HTLV-III infection has a long latent period. The prevalence of AIDS in different geographic areas and among different risk groups appears to depend in part on duration of exposure. Co-factors for AIDS outcome such as manner and route of exposure, underlying immune status, and host susceptibility are also likely to play a role in risk.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Diseases; Epidemiologic Methods; Hiv Infections; Literature Review; Population At Risk; Research Methodology; Viral Diseases

Mesh:

Substances:

Year:  1985        PMID: 2996397     DOI: 10.7326/0003-4819-103-5-665

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

2.  Hormone pattern in pharmacologically feminized male transsexuals in the California State prison system.

Authors:  L J Valenta; A N Elias; E S Domurat
Journal:  J Natl Med Assoc       Date:  1992-03       Impact factor: 1.798

3.  Update on AIDS for the family physician.

Authors:  M B Garvey
Journal:  Can Fam Physician       Date:  1987-05       Impact factor: 3.275

4.  Intestinal CD4 Depletion in HIV / SIV Infection.

Authors:  Ronald S Veazey
Journal:  Curr Immunol Rev       Date:  2019

5.  Immune impairments and antibodies to HTLVIII/LAV in asymptomatic male homosexuals in Israel: relevance to the risk of acquired immune deficiency syndrome (AIDS).

Authors:  Z Bentwich; C Saxinger; Z Ben-Ishay; R Burstein; Y Berner; M Pecht; N Trainin; S Levin; Z T Handzel
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

6.  Heterosexual transmission of AIDS: no time for complacency.

Authors:  N Clumeck
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

7.  Sequential changes in antibody levels to the env and gag antigens in human immunodeficiency virus infected subjects.

Authors:  N Manca; F di Marzo Veronese; D D Ho; R C Gallo; M G Sarngadharan
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

8.  Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.

Authors:  P N Fultz; H M McClure; R B Swenson; C R McGrath; A Brodie; J P Getchell; F C Jensen; D C Anderson; J R Broderson; D P Francis
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

9.  Methylation as a modulator of expression of human immunodeficiency virus.

Authors:  D P Bednarik; J D Mosca; N B Raj
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

Review 10.  The neuropathology of AIDS. UCLA experience and review.

Authors:  K H Anders; W F Guerra; U Tomiyasu; M A Verity; H V Vinters
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.